Key facts
- It has raised $260K; the latest was Later Stage VC ($260K) in Dec 2024.
- Notable investors include Scottish Enterprise, Heriot-Watt University, Merck, SantanderX, UK Research and Innovation Medical Research Council.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Natantis
- ·The full record, as it builds
Funding rounds
No funding rounds for Natantis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Natantis
Developer of a cell-free deoxyribonucleic acid metagenomic workflow intended to identify sepsis-causing pathogens. The company's technology identifies viruses, bacteria, fungi, and various parasites at the species level, directly from a venous blood sample, providing clinicians with a sequencing assay and delivering a clinically actionable result in the form of a list of top pathogens.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Website
- natantis.com/
- Ownership
- Privately Held (backing)
Natantis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Natantis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Natantis in its N-PORT filings yet. We sweep new filings monthly.